Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib
- PMID: 32060054
- DOI: 10.1158/2159-8290.CD-RW2020-025
Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib
Abstract
In a phase Ib trial, osimertinib plus savolitinib showed efficacy in non-small cell lung cancer.
©2020 American Association for Cancer Research.
Comment on
-
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.Lancet Oncol. 2020 Mar;21(3):373-386. doi: 10.1016/S1470-2045(19)30785-5. Epub 2020 Feb 3. Lancet Oncol. 2020. PMID: 32027846 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
